The news that one of America's TV icons is suffering from cancer brought sadness. Learning the type of cancer she had made some squeamish.
The death rate due to cancer has declined in the United States in recent years, largely due to better prevention and treatment. In fact, 650,000 lives were spared from cancer between 1990 to 2005, according to new statistics from the American Cancer Society.
Is it necessary to have a colonoscopy when you're over age 50?
Pancreatic cancer is rare and extraordinarily lethal, experts say.
A new study on colonoscopies raises questions about this colon cancer detection method. CNN's Dr. Sanjay Gupta reports.
A new study by Canadian researchers, published in the Annals of Internal Medicine, found that colonoscopies are still very effective in detecting colorectal cancer, but they're only good at doing so in cancers found on the left side of the colon, not on the right side.
People with diagnosed colon cancer who have received treatment and who eat a "Western diet," high in red meat, refined grains, fat and sugar, are more likely to have a recurrence of colon cancer and die from it, compared with patients who eat a "prudent" diet high in fruits, vegetables, poultry and fish.
Many colon cancer patients aren't getting the screenings recommended after surgery to make sure the disease hasn't returned, new research shows
The Ugly Betty star appears with colon cancer survivor Carmen Marc Valvo
U.S. cancer deaths rose by more than 5,000 in 2005, a somewhat disappointing reversal of a two-year downward trend, the American Cancer Society reported
Scientists have traced a genetic mutation that causes a hereditary form of colon cancer back to a single couple who left England for America in the 1630s
Progress against colorectal cancer has helped lower cancer death rates in Americans. CNN's Elizabeth Cohen reports.
Biotech developer Genentech reported first-quarter earnings and revenue Wednesday that beat analysts' expectations.
ImClone Systems Inc. said Tuesday that a late-stage trial of its cancer drug Erbitux failed to extend survival in patients with pancreatic cancer, sending its shares down more than 7.5 percent.
Stalled sales, failed drug experiments and an SEC inquiry are among the problems nagging at Amgen and Genentech as the world's two biggest biotech companies get set to report first-quarter earnings.
Stocks managed modest gains Friday afternoon, with the day's biggest push coming from a somewhat upbeat housing report and strength in auto stocks.
An upbeat housing market report helped lift the blue chips Friday afternoon, but gains were limited as investors worried about the ramifications of Iran seizing 15 British marines.
The biotech ImClone's stock price surged Friday following some bad news about its competitor Amgen's cancer drug Vectibix.
Stocks struggled Friday morning as investors welcomed the positive aspects of the morning's housing sales report, but held back amid higher oil prices and rising Treasury yields.
Here are some of the stocks actively trading on Friday:
Bristol-Myers Squibb executives blamed flagging fourth-quarter earnings on generic competition against its top-selling drug, the blood thinner Plavix but said Thursday the problem will be temporary thanks to pending products.
Genentech will unveil new details this weekend on tests of Avastin, one of its biggest-selling medicines, as it seeks to find new markets for the cancer drug.
The biotech Genentech reported a surge in earnings for 2006 and beat analyst projections for the fourth quarter.
New study results could broaden the use of colon cancer drug Erbitux, but analysts have mixed opinions as to whether this means a boost in sales and royalties for ImClone and Bristol-Myers Squibb.
Biotechs didn't do so well in 2006, but analysts are expecting a strong recovery for 2007, particularly for Big Biotech.
Celebrex, an arthritis painkiller from Pfizer, could be used to prevent colorectal cancer, according to studies revealed today by the American Association for Cancer Research.
Genentech's stock jumped more than 5 percent on Friday after the biotech said its earnings would surge by up to 50 percent in 2006.
Fortune: Staying the Courseupdated: Mon Nov 14 2005 00:01:00
I WAS GENENTECH'S chief medical officer when we began clinical-trial studies of Avastin in 1997. The hypothesis was that Avastin could stun a tumor--keep it from growing beyond the size of a BB pel...
People who eat too much red and processed meat increase their risk of bowel cancer by up to a third, according to a new study.
Genentech could be one of the most promising biotechs on the market, but is its share price justified?
Cholesterol lowering drugs called 'statins' may play a role in colorectal cancer prevention, according to a new study presented at a major cancer conference Sunday.
It's strange to think that I can still remember the smell after all this time. The year was 1978, not long after my 15th birthday, and I'd sneaked into my brother's bedroom. There, on a wall of she...
Actuaries, not economists, are the truly dismal scientists. Consider some actuarial projections about the graying America of 2050: One in 26 of us will have Alzheimer's disease, compared with one i...
When I hear that a patient has been diagnosed with colon cancer or, worse yet, that the cancer has spread outside the colon, I feel a twinge of pain. Almost all colon cancers are preventable. End o...
© 2013 Cable News Network. Turner Broadcasting System, Inc. All Rights Reserved.
|